


The Claims are:

Claim 1. (canceled) A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

Q is an aryl, a 5- or 6-membered heteroaryl, or a 4–8-membered heterocyclic ring;
T together with the –N=C– to which it is attached forms a heteroaryl ring, or a heterocyclic ring where the N=C bond is the only site of unsaturation;

R¹ and R² each independently are hydrogen, hydroxy, halogen, cyano, nitro, vinyl, ethynyl, methoxy, OCF_nH_{3-n}, –N(C₀₋₄alkyl)(C₀₋₄alkyl), CHO, or C₁₋₂alkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, –N(C₀₋₂alkyl)(C₀₋₂alkyl), SOCH₃, or SO₂CH₃ substituents; or R¹ and R² together form a carbocyclic or heterocyclic ring; or R¹ and R² may be taken together to represent an oxygen atom attached to the ring via a double bond;

R³ and R⁴ each independently are hydrogen, halogen, OCF_nH_{3-n}, methoxy, CO₂R⁷⁷, cyano, nitro, CHO, CONR⁹⁹R¹⁰⁰, CON(OCH₃)CH₃, or C₁₋₂alkyl, heteroaryl, or C₃₋₇cycloalkyl optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy, –NHCO₂CH₃, or –N(C₀₋₂alkyl)(C₀₋₂alkyl) substituents; or R³ and R⁴ together form a 5–8-membered aromatic, heteroaromatic, carbocyclic, or heterocyclic ring;

R⁵ and R⁶ each independently are hydrogen, hydroxy, halogen, cyano, nitro, CO₂R⁷, CHO, COR⁸, C(OH)R⁷R⁸, C(=NOR⁷)R⁸, CONR⁹R¹⁰, SR⁷, SOR⁸, SO₂R⁸,

$\text{SO}_2\text{NR}^9\text{R}^{10}$, $\text{CH}_2\text{NR}^9\text{R}^{10}$, NR^9R^{10} , $\text{N}(\text{C}_{0-4}\text{alkyl})\text{SO}_2\text{R}^8$, NHCOR^7 , or $\text{C}_{1-4}\text{alkyl}$ group, $\text{C}_{2-4}\text{alkenyl}$ group, $\text{C}_{2-4}\text{alkynyl}$ group, $\text{C}_{1-4}\text{alkoxy}$ group, aryl group, or heteroaryl group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, $\text{C}_{1-2}\text{alkoxy}$, $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, $\text{C}_{1-2}\text{alkyl}$, $\text{CF}_n\text{H}_{3-n}$, aryl, heteroaryl, $-\text{COC}_{1-2}\text{alkyl}$, $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, SCH_3 , SOCH_3 , SO_2CH_3 , or $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ substituents; or R^5 and R^6 together form a 5-8-membered carbocyclic or heterocyclic ring;

R^7 and R^{77} each independently are hydrogen, or $\text{C}_{1-4}\text{alkyl}$ group, $\text{C}_{2-4}\text{alkenyl}$ group, $\text{C}_{2-4}\text{alkynyl}$ group, $\text{C}_{3-7}\text{cycloalkyl}$ group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, $\text{C}_{1-2}\text{alkoxy}$, $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, $\text{C}_{1-2}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkyl}$, 4-7-membered heterocyclic ring, $\text{CF}_n\text{H}_{3-n}$, aryl, heteroaryl, CO_2H , $-\text{COC}_{1-2}\text{alkyl}$, $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, SOCH_3 , SO_2CH_3 , or $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ substituents;

R^8 is $\text{C}_{1-4}\text{alkyl}$ group, $\text{C}_{2-4}\text{alkenyl}$ group, $\text{C}_{2-4}\text{alkynyl}$ group, $\text{C}_{3-7}\text{cycloalkyl}$ group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, $\text{C}_{1-2}\text{alkoxy}$, $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, $\text{C}_{1-2}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkyl}$, 4-7-membered heterocyclic ring, $\text{CF}_n\text{H}_{3-n}$, aryl, heteroaryl, CO_2H , $\text{COC}_{1-2}\text{alkyl}$, $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, SOCH_3 , SO_2CH_3 , or $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ substituents;

R^9 , R^{10} , R^{99} , and R^{100} each independently are hydrogen, or $\text{C}_{1-4}\text{alkyl}$ group, $\text{C}_{3-7}\text{cycloalkyl}$ group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy, $\text{C}_{1-2}\text{alkoxy}$, $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, $\text{C}_{1-2}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkyl}$, 4-7-membered heterocyclic ring, $\text{CF}_n\text{H}_{3-n}$, aryl, heteroaryl, $\text{COC}_{1-2}\text{alkyl}$, $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$, SOCH_3 , SO_2CH_3 , or $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ substituents; or R^9 and R^{10} or R^{99} and R^{100} together form a 6-8-membered heterobicyclic ring system or a 4-8-membered heterocyclic ring which optionally is substituted with 1-2 independent $\text{C}_{1-2}\text{alkyl}$, CH_2OCH_3 , $\text{COC}_{0-2}\text{alkyl}$, hydroxy, or SO_2CH_3 substituents;

n is 1, 2 or 3;

m is 0 or 1; and

the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (*E*)-configuration.

Claim 2. **(canceled)** A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a double bond.

Claim 3. **(canceled)** A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond.


Claim 4. **(canceled)** A compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond, and the absolute configuration at the asymmetric centre α to the amide carbonyl carbon is (*R*).

Claim 5. **(canceled)** A compound according to claim 1, wherein m is 0.

Claim 6. **(canceled)** The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is thienyl, furyl, thiazolyl, pyridyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyranyl or 1,1-dioxo-tetrahydrothiopyranyl.


Claim 7. **(canceled)** A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein Q is 4-tetrahydropyranyl.

Claim 8. **(canceled)** The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the group of formula




is thiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrazinyl, or pyridyl.

Claim 9. (**canceled**) A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein the group of formula



is 2-pyrazinyl or 2-thiazolyl.

Claim 10. (**canceled**) A compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein the group of formula



is 2-thiazolyl, R³ is 5-fluoro and R⁴ is hydrogen.

Claim 11. (**canceled**) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R³ and R⁴ are independently selected from hydrogen, halogen, and methyl.

Claim 12. (**canceled**) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁵ is SOR⁸, SO₂R⁸, or SO₂NR⁹R¹⁰.

Claim 13. (**canceled**) A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R⁸ is C₁₋₄alkyl or C₃₋₇cycloalkyl.

Claim 14. **(canceled)** A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁵ is SO₂C₃₋₄cycloalkyl.

Claim 15. **(canceled)** A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁶ is hydrogen.

Claim 16. **(canceled)** A compound selected from:

(E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-3-ylacrylamide;
(E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(E)-3-Furan-2-yl-2-(4-methanesulfonylphenyl)-N-thiazol-2-ylacrylamide;
(E)-2-(4-Methanesulfonylphenyl)-3,N-bisthiazol-2-ylacrylamide;
(E)-2-(4-Methanesulfonylphenyl)-3-(5-methylthiophen-2-yl)-N-thiazol-2-ylacrylamide;
(E)-3-(5-Chlorothiophen-2-yl)-2-(4-methanesulfonylphenyl)-N-thiazol-2-ylacrylamide;
(E)-2-(4-Methanesulfonylphenyl)-3-thiazol-5-yl-N-thiazol-2-ylacrylamide;
2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-2-ylpropionamide;
2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;
2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;
N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;
(E)-2-(4-Bromophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;
(E)-2-(4-Methoxyphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;
(E)-3-(Tetrahydropyran-4-yl)-N-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;
(E)-3-(Tetrahydrothiopyran-4-yl)-N-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;

(*E*)-3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,3]triazol-1-ylphenyl)acrylamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-trifluoromethylsulfanylphenyl)propionamide;

2-(4-Methylsulfanyl methylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methanesulfonylphenyl)-*N*-(1*H*-pyrazol-3-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-pyridin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)propionamide;

N-(4,5-Dihydrothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

N-(1*H*-Imidazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

N-Benzothiazol-2-yl-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,3,4]thiadiazol-2-ylpropionamide;

2-(4-Methanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Fluoropyridin-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-(5-methylthiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-(4-methylthiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,2,4]thiadiazol-5-ylpropionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

2-(4-Methanesulfonylphenyl)-*N*-(5-nitrothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;

(*E*)-*N*-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-3-furan-2-yl-2-(4-methanesulfonylphenyl)acrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-3-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-pyridin-3-ylacrylamide;

N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylpropionamide;

N-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiazol-5-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-*N*-(5-chlorothiazol-2-yl)-3-furan-2-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-3-furan-2-yl-*N*-pyrimidin-4-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-*N*-(5-bromothiazol-2-yl)-3-furan-2-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-3-furan-2-yl-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-3-furan-2-yl-*N*-(5-methylthiazol-2-yl)acrylamide;
(*E*)-*N*-Benzothiazol-2-yl-2-(4-bromophenyl)-3-furan-2-ylacrylamide;
(*E*)-2-(4-Bromophenyl)-*N*-(4,5-dimethylthiazol-2-yl)-3-furan-2-ylacrylamide;
(*E*)-2-(4-Bromophenyl)-*N*-(5-bromothiazol-2-yl)-3-thiophen-2-ylacrylamide;
(*E*)-2-(4-Bromophenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(*E*)-2-(4-Bromophenyl)-*N*-[1,3,4]thiadiazol-2-yl-3-thiophen-2-ylacrylamide;
(*E*)-2-(4-Bromophenyl)-*N*-(5-methylthiazol-2-yl)-3-thiophen-2-ylacrylamide;
(*E*)-2-(4-Bromophenyl)-*N*-(5-chlorothiazol-2-yl)-3-thiophen-2-ylacrylamide;
(*E*)-3-Furan-2-yl-2-(4-methoxyphenyl)-*N*-thiazol-2-ylacrylamide;
(*E*)-3-Furan-2-yl-2-(4-methoxyphenyl)-*N*-(5-methylthiazol-2-yl)acrylamide;
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-thiophen-2-ylacrylamide;
(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-nitrophenyl)-3-thiophen-2-ylacrylamide;
(*E*)-2-(4-Nitrophenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;
(*E*)-2-(4-Cyanophenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyanophenyl)-3-thiophen-2-ylacrylamide;
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyanophenyl)-3-phenylacrylamide;
2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;
(*E*)-2-Phenyl-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;
(*E*)-2-Phenyl-*N*-[1,3,4]thiadiazol-2-yl-3-thiophen-2-ylacrylamide;
(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;
(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;
(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

(*E*)-*N*-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

(*E*)-2-(4-Methanesulfinylphenyl)-3-(tetrahydrothiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfinylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

N-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methoxymethylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylsulfanyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-(3-Methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methylsulfanyl-3-nitrophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

(*E*)-2-(4-Nitrophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

2-(3-Fluoro-4-methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-formylthiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

2-(3-Bromo-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Ethylsulfamoylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Ethylsulfamoylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide

(2*R*)-3-(Tetrahydropyran-4-yl)-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylpropionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,2,4]thiadiazol-5-ylpropionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-*N*-(5-Fluoropyridin-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluoropyridin-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-isoxazol-3-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-pyridin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-(6-methoxypyrimidin-4-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluoropyridin-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

2-(3-Fluoro-4-methanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Ethanesulfonylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Ethanesulfonylphenyl)-*N*-isoxazol-3-yl-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Fluorothiazol-2-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-[4-(Propane-1-sulfonyl)phenyl]-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(3-Methyl-[1,2,4]thiadiazol-5-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(1-Methyl-1*H*-pyrazol-3-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-Phenyl-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Formylphenyl)-*N*-(5-formylthiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Formylthiazol-2-yl)-2-phenyl-3-(tetrahydropyran-4-yl)acrylamide;
2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]thiazole-5-carboxylic acid;

2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]thiazole-5-carboxylic acid methoxy-methyl-amide;

2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]thiazole-5-carboxylic acid methylamide;

(*E*)-2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acryloylamino]thiazole-5-carboxylic acid methylamide;

N-(5-Formylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Hydroxymethylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Cyanothiazol-2-yl)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Cyanothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

Methyl {2-[2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]-thiazol-5-ylmethyl} carbamate;

(*E*)-3-(1-Formylpiperidin-4-yl)-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Methanesulfonylphenyl)-3-(1-oxohexahydro-1 λ^4 -thiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-3-(1,1-Dioxohexahydro-1 λ^6 -thiopyran-4-yl)-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(1-oxohexahydro-1 λ^4 -thiopyran-4-yl)acrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-3-(1,1-dioxohexahydro-1 λ^6 -thiopyran-4-yl)-2-(4-methanesulfonylphenyl)acrylamide;

2-(3-Fluoro-4-methanesulfinylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Fluoro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

N-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-Hydroxyphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Methanesulfonylaminophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylmethylsulfanyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridin-3-ylsulfanyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylmethanesulfonyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-(4-Methoxymethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Tetrahydropyran-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylmethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridin-3-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyanomethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,2,4]Oxadiazol-3-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,3]Dioxolan-2-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Propane-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Oxetane-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*S*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*R*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(2-Oxopropane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-2-sulfinyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyrazine-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyrazine-2-sulfinyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyrimidine-5-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Amino-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Chloro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Morpholine-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Sulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Dimethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methylpiperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-3-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-{4-[(tetrahydropyran-4-ylmethyl)sulfamoyl]phenyl}-*N*-thiazol-2-ylpropionamide;

2-{4-[(Tetrahydrofuran-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-[4-(thiomorpholine-4-sulfonyl)phenyl]propionamide;

2-[4-(Azetidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,4]Oxazepane-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Cyclopropylmethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-{4-[(thiophen-2-ylmethyl)sulfamoyl]phenyl}propionamide;

2-[4-((1*S*,4*S*)-2-Oxa-5-azabicyclo[2.2.1]heptane-5-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methyl-[1,4]diazepane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((2*R*)-2-Methoxymethylpyrrolidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylsulfamoyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-[4-(Imidazole-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

N-(5-Chlorothiazol-2-yl)-2-[4-(2-dimethylaminoethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Chlorothiazol-2-yl)-2-[4-(3-hydroxyazetidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Chlorothiazol-2-yl)-2-[4-((3*S*)-3-hydroxypyrrolidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Chlorothiazol-2-yl)-2-[4-(4-methylpiperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Chlorothiazol-2-yl)-2-[4-(piperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Chlorothiazol-2-yl)-2-[4-(2-methylaminoethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

2-[4-(2-Aminoethylsulfamoyl)phenyl]-*N*-(5-chlorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

N-Ethyl-4-[2-(tetrahydropyran-4-yl)-1-(thiazol-2-ylcarbamoyl)ethyl]benzamide;

2-(3-Chloro-4-methanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonyl-3-trifluoromethylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide; and

2-(3,4-Dichlorophenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

or a pharmaceutically acceptable salt thereof.

Claim 17. (**canceled**) A compound selected from:

(*E*)-2-(4-Methanesulfonylphenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;

(*E*)-3-Furan-2-yl-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylacrylamide;

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;

(*E*)-3-(Tetrahydrothiopyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;

(*E*)-3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,3]triazol-1-ylphenyl)acrylamide;

N-Benzothiazol-2-yl-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,2,4]thiadiazol-5-ylpropionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;

(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfinylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;
2-(4-Methoxymethylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;
(*E*)-2-(4-Nitrophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-(tetrahydropyran-4-yl)acrylamide;
(*E*)-2-(4-Methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;
(*E*)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*[1,2,4]thiadiazol-5-ylpropionamide;
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluoropyridin-2-yl)-3-(tetrahydropyran-4-yl)propionamide;
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;
(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(*2R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Methanesulfonylaminophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

2-[4-(Pyridin-3-ylsulfanyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methoxymethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Tetrahydropyran-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylmethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,2,4]Oxadiazol-3-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,3]Dioxolan-2-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Oxetane-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*S*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*R*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(2-Oxopropane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Dimethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methylpiperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-3-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Azetidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Cyclopropylmethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-{4-[(thiophen-2-ylmethyl)sulfamoyl]phenyl}propionamide;

2-[4-((1*S*,4*S*)-2-Oxa-5-azabicyclo[2.2.1]heptane-5-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methyl-[1,4]diazepane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Imidazole-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

N-(5-Chlorothiazol-2-yl)-2-[4-(2-dimethylaminoethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide; and

N-(5-Chlorothiazol-2-yl)-2-[4-(piperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

or a pharmaceutically acceptable salt thereof.

Claim 18. (**canceled**) A compound selected from:

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide; and

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;


or a pharmaceutically acceptable salt thereof.

Claim 19. (**canceled**) (2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

Claim 20. (**canceled**) (2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

Claim 21. (**canceled**) (*E*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide, or a pharmaceutically acceptable salt thereof.

Claim 22. (**canceled**) A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is 4-tetrahydropyranyl;

T together with the $-\text{N}=\text{C}-$ to which it is attached forms a 2-pyrazinyl or 2-thiazolyl ring;

R^1 and R^2 are hydrogen;

R^3 and R^4 each independently are hydrogen or fluoro;

R^5 is SO_2R^8 , or $\text{SO}_2\text{NR}^9\text{R}^{10}$;

R^6 is hydrogen;


R^8 is a C_{3-5} cycloalkyl group or a 4–6-membered heterocyclic group, and, in addition, when the dotted line together with the solid line forms a double bond R^8 may be a C_{1-3} alkyl group;

R^9 and R^{10} are independently C_{0-4} alkyl, provided that R^9 and R^{10} are not both hydrogen;

m is 0; and

the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (*E*)-configuration.

Claim 23. (canceled) A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is 4-tetrahydropyranyl;

T together with the $-\text{N}=\text{C}-$ to which it is attached forms a 2-pyrazinyl or 2-thiazolyl ring;

R^1 and R^2 are hydrogen;

R^3 and R^4 each independently are hydrogen or fluoro;

R^5 is SO_2R^8 ;

R^6 is hydrogen;

R^8 is a C_{3-4} cycloalkyl group and, in addition, when the dotted line together with the solid line forms a double bond R^8 may be a C_{1-3} alkyl group;

m is 0; and

the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (*E*)-configuration.

Claim 24. (canceled) A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claim 25. (canceled) A method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an


effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

Claim 26. (canceled) A method of prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

Claim 27. (canceled) The method according to claim 26 wherein the compound according to any one of claim 1 is administered in combination with one or more other anti-hyperglycemic agents or anti-diabetic agents.


Claim 28. (canceled) A method of prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

Claim 29. (canceled) A process for the preparation of a compound of Formula (Ia)




(Ia)

said process comprising a step of the condensation of a compound of Formula (IV):




with a compound of Formula (V):




wherein Q , T , R^1 to R^6 , m and Δ are as defined in claim 1.

Claim 30. (canceled) A process for the preparation of a compound of Formula (Ib)




(Ib)

said process comprising a step of the condensation of a compound of Formula (VIII):




with a compound of Formula (V):



wherein Q, T, R¹ to R⁶ and m are as defined in claim 1.

Claim 31. (canceled) A compound of formula (IV):



wherein Q is 4-tetrahydropyranyl;

R¹ and R² are hydrogen;

R⁵ is SO₂R⁸, or SO₂NR⁹R¹⁰;

R⁶ is hydrogen;

R⁸ is a C₁₋₃alkyl group, a C₃₋₅cycloalkyl group or a 4-6-membered heterocyclic group;

R⁹ and R¹⁰ are independently C₀₋₄alkyl, provided that R⁹ and R¹⁰ are not both hydrogen;

m is 0; and

the dotted line together with the solid line forms a double bond, and Δ indicates that the double bond has the (E)-configuration.

Claim 32. (canceled) A compound of Formula (IV) selected from:

(E)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;


(E)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;

(E)-2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;

(E)-2-(4-Ethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid; and

(E)-2-[4-(Propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylic acid.

Claim 33. (canceled) A compound of formula (VIII):



Q is 4-tetrahydropyranyl;

R¹ and R² are hydrogen;

R⁵ is SO₂R⁸, or SO₂NR⁹R¹⁰;

R⁶ is hydrogen;

R⁸ is a C₃₋₅cycloalkyl group or a 4–6-membered heterocyclic group;

R⁹ and R¹⁰ are independently C₀₋₄alkyl, provided that R⁹ and R¹⁰ are not both hydrogen; and

m is 0.

Claim 34. (canceled) A compound of Formula (VIII) selected from:

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-propionic acid;

2-(4-Methoxymethanesulfanylphenyl)-3-(tetrahydropyran-4-yl)-propionic acid;

2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;

2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;


(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)propionic acid; and

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid.

Claim 35. (canceled) 5-Fluorothiazol-2-ylamine or an amide or acid addition salt thereof.

Claim 36. (new) A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

Q is 4-tetrahydropyranyl;

T together with the $-N=C-$ to which it is attached forms a 2-pyrazinyl or 2-thiazolyl ring;

R^1 and R^2 are hydrogen;

R^3 and R^4 each independently are hydrogen or fluoro;

R^5 is SO_2R^8 ;

R^6 is hydrogen;

R^8 is a C_{3-4} cycloalkyl group and, in addition, when the dotted line together with the solid line forms a double bond R^8 may be a C_{1-3} alkyl group;

m is 0; and

the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (*E*)-configuration.


Claim 37. (new) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a double bond.

Claim 38. (new) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond.

Claim 39. (new) A compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond, and the absolute configuration at the asymmetric centre α to the amide carbonyl carbon is (*R*).

Claim 40. (new) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein R^3 is fluoro or hydrogen and R^4 is hydrogen.

Claim 41. (new) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the group of formula




is 2-thiazolyl;

R^3 is 5-fluoro; and

R^4 is hydrogen.

Claim 42. (new) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the group of formula



is 2-pyrazinyl;

R^3 is hydrogen; and

R^4 is hydrogen.

Claim 43. (**new**) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein R⁵ is SO₂C₃₋₄cycloalkyl.

Claim 44. (**new**) A compound selected from:

2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;

2-(4-cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(E)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;

(E)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;

(2R)-3-(tetrahydropyran-4-yl)-2-(4-methanesulfonylphenyl)-N-thiazol-2-ylpropionamide;

(2R)-2-(4-cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2R)-2-(4-cyclopropanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2R)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;

(2R)-2-(4-cyclobutanesulfonylphenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2R)-2-(4-cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(E)-2-(4-cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-fluorothiazol-2-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

or a pharmaceutically acceptable salt thereof.

Claim 45. (new) A compound consisting of (*2R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

Claim 46. (new) A compound consisting of (*2R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

Claim 47. (new) A pharmaceutical composition comprising a compound according to claim 36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


Claim 48. (new) A method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a compound according to claim 36, or a pharmaceutically acceptable salt thereof.

Claim 49. (new) A method of prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound according to claim 36, or a pharmaceutically acceptable salt thereof.


Claim 50. (new) The method according to claim 49 wherein the compound according to claim 36 is administered in combination with one or more other anti-hyperglycemic agents or anti-diabetic agents.

Claim 51. (new) A method of prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound according to claim 36, or a pharmaceutically acceptable salt thereof.


Claim 52. (new) A process for the preparation of a compound of Formula (Ia)



said process comprising a step of the condensation of a compound of Formula (IV):




with a compound of Formula (V):




wherein Q, T, R¹ to R⁶, m and Δ are as defined in claim 36.


Claim 53. (new) A process for the preparation of a compound of Formula (Ib)



said process comprising a step of the condensation of a compound of Formula (VIII):




with a compound of Formula (V):



wherein Q, T, R¹ to R⁶ and m are as defined in claim 36.

Claim 54. (new) A compound of formula (IV):




wherein Q is 4-tetrahydropyranyl;
 R^1 and R^2 are hydrogen;
 R^5 is SO_2R^8 ;
 R^6 is hydrogen;
 R^8 is a C_{3-4} cycloalkyl group or a C_{1-3} alkyl group;
m is 0; and

Δ indicates that the double bond has the (*E*)-configuration.

Claim 55. (new) A compound according to claim 54, selected from:

(*E*)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;
(*E*)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid; and
(*E*)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylic acid.

Claim 56. (new) A compound of formula (VIII):



wherein Q is 4-tetrahydropyranyl;
 R^1 and R^2 are hydrogen;
 R^5 is SO_2R^8 ;
 R^6 is hydrogen;
 R^8 is a C_{3-4} cycloalkyl group; and
m is 0.

Claim 57. (**new**) A compound according to claim 56 of Formula (VIII) selected from:

2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;
2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;
(*2R*)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;

and

(*2R*)-2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid.

Claim 58. (**new**) A compound consisting of 5-fluorothiazol-2-ylamine or an amide or acid addition salt thereof.